Purpose: The auditory brainstem response (ABR) is a powerful tool for making clinical decisions about the presence, degree, and type of hearing loss in individuals in whom behavioral hearing thresholds cannot be obtained or are not reliable. Although the test is objective, interpretation of the results is subjective.
Method: This review provides information about evidence-based criteria, suggested by the 2013 Newborn Hearing Screening Program guidelines, and the use of cross-check methods for making valid interpretations about hearing status from ABR recordings.
Results: The use of an appropriate display scale setting, templates of expected response properties, and objective criteria to estimate the residual noise, signal level, and signal-to-noise ratio will provide quality data for determining ABR thresholds. Cross-checks (e.g., immittance measures, otoacoustic emissions testing, functional indications of a child's hearing) are also needed to accurately interpret the ABR.
Conclusions: Using evidence-based ABR signal detection criteria and considering the results within the context of other physiologic tests and assessments of hearing function will improve the clinician's accuracy for detecting hearing loss and, when present, the degree of hearing loss. Diagnostic accuracy will ensure that appropriate remediation is initiated and that children or infants with normal hearing are not subjected to unnecessary intervention.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1044/2017_AJA-17-0074 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Canadian Association of Radiologists Central Nervous System Diagnostic Imaging Referral Guideline.
Can Assoc Radiol J
January 2025
North York General Hospital, Toronto, ON, Canada.
The Canadian Association of Radiologists (CAR) Central Nervous System Expert Panel is made up of physicians from the disciplines of radiology, emergency medicine, neurosurgery, and neurology, a patient advisor, and an epidemiologist/guideline methodologist. After developing a list of 24 clinical/diagnostic scenarios, a rapid scoping review was undertaken to identify systematically produced referral guidelines that provide recommendations for one or more of these clinical/diagnostic scenarios. Recommendations from 55 guidelines and contextualization criteria in the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) for guidelines framework were used to develop 51 recommendation statements across the 24 scenarios.
View Article and Find Full Text PDFAssociations of modifiable dementia risk factors with dementia and cognitive decline: evidence from three prospective cohorts.
Front Public Health
January 2025
College of Physical Education and Health, Guangxi Normal University, Guilin, China.
Objective: This study aims to assess the relationship between modifiable dementia risk factors and both dementia and cognitive decline.
Methods: Data were obtained from the Health and Retirement Study (HRS) [2008-2020], the China Health and Retirement Longitudinal Study (CHARLS) [2011-2020], and the English Longitudinal Study of Ageing (ELSA) [2010-2020]. After adjusting for confounding factors, multivariable logistic regression was utilized to analyze the relationship between modifiable dementia risk factors and dementia, while multivariable linear regression was employed to examine the relationship between these risk factors and cognitive decline.
The chiisanoside derivatives present in the leaves of activate autophagy through the LRP6/GSK3β axis and thereafter inhibit oxidative stress, thereby counteracting cisplatin-induced ototoxicity.
Front Pharmacol
January 2025
College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun, Jilin, China.
Introduction: Cisplatin is extensively employed in the treatment of multiple solid malignant tumors. Nevertheless, side effects such as cisplatin-induced ototoxicity (CIO) pose obstacles to tumor therapy.The important natural product chiisanoside from has abundant activity against CIO.
View Article and Find Full Text PDFAudiometric Outcomes of Auditory Brainstem Implantation during Vestibular Schwannoma Resection in NF2 Patients.
J Neurol Surg B Skull Base
February 2025
Department of Neurosurgery, UC San Diego Medical Center, San Diego, California, United States.
Many patients with neurofibromatosis type 2 (NF2) suffer from sensorineural hearing loss, and associated cochlear nerve compromise in NF2 patients makes auditory brainstem implant (ABI) an attractive treatment option. The long-term outcomes and benefits of the device are still being explored. A retrospective review was conducted for 11 ABI recipients at a single-institution tertiary center between November 2017 and August 2022.
View Article and Find Full Text PDFCochlear implantation and cognitive function in the older adult population: current state of the art and future perspectives.
Braz J Otorhinolaryngol
January 2025
Antwerp University Hospital (UZA), Department of Otorhinolaryngology, Head and Neck Surgery, Edegem, Belgium; University of Antwerp, Faculty of Medicine and Health Sciences, Department of Translational Neurosciences, Resonant Labs Antwerp, Antwerp, Belgium.
Objectives: Hearing loss is associated with increased cognitive decline and incident dementia in older adults. Given the rapidly rising incidence of dementia, management of modifiable risk factors such as hearing loss, is essential to mitigate the impact on the individual and society in general. In this narrative review, we discuss the current state-of-art with respect to studying cognitive function before and after cochlear implantation in the elderly population.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!